FDA approved durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
PolyPid Ltd. announced a new research and development collaboration with ImmunoGenesis Inc. The collaboration focuses on the development of novel formulations utilizing PolyPid’s experience with its proprietary PLEX Technology and ImmunoGenesis’ potent STimulator of INterferon Genes agonist drug candidate to potentially enhance treatment for solid tumors.
Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
NCI is temporarily reducing its paylines as the federal government is being funded at FY2024 levels via a continuing resolution that extends until Dec. 20, delaying the budgeting process for most federal agencies in the new fiscal year.
NCI is establishing an Early-Onset Cancer Initiative to address the reported rise in early-onset cancer. The initiative will focus on the biological mechanisms of early-onset cancer, the interactions between several known risk factors, and prevention strategies.
Robert F. Kennedy Jr., an anti-vaccine activist whom Trump has chosen to run HHS, would have the capacity to roll back core public health protections, including protections for people with cancer, and dismantle research related to infectious diseases, public health experts warn.
Michael Wong joined Roswell Park Comprehensive Cancer Center as the center’s first physician-in-chief.
Andrew M. EvensPhillip ScheinbergThe British Journal of Haematology announced the appointment of Andrew M. Evens as its editor-in-chief, effective Jan. 1, 2025.
